OPEXA THERAPEUTICS, INC. (NASDAQ:OPXA) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
On August 14, 2017, Opexa Therapeutics, Inc. filed its Quarterly Report on Form10-Q for the quarter ended June 30, 2017 and announced its results of operations in a press release. A copy of the press release announcing the results is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
Press release issued by Opexa Therapeutics, Inc. on August 14, 2017. |
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities under that Section, nor be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933.
Opexa Therapeutics, Inc. ExhibitEX-99.1 2 opxa_ex991.htm PRESS RELEASE Blueprint Exhibit 99.1 Opexa Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update THE WOODLANDS,…To view the full exhibit click here
About OPEXA THERAPEUTICS, INC. (NASDAQ:OPXA)
Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology. The Company’s product candidates include Tcelna and OPX-212. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient’s immune response profile to myelin. Tcelna is designed to reduce the number and/or functional activity of specific subsets of myelin-reactive T-cells (MRTCs) known to attack myelin. Tcelna is manufactured using its method for the production of an autologous T-cell product. In addition to the ongoing clinical development of Tcelna, the Company is developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.